RBC Capital Maintains Outperform on Marinus Pharma, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Marinus Pharma (NASDAQ:MRNS) and raised the price target from $20 to $21.
September 20, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an 'Outperform' rating on Marinus Pharma and raised the price target from $20 to $21, which could positively impact the stock.
The 'Outperform' rating indicates that the analyst expects the stock to do better than the market average. The increase in price target from $20 to $21 suggests that the analyst sees more upside potential in the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100